Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIIb, Open Label, Multi Center Extension Study of V72_28 to Assess Antibody Persistence, and the Safety and Tolerability of a Booster Dose After the Completion of the Vaccination Course in Study V72_28

NCT01894919 is registered in ClinicalTrials.gov with Novartis Vaccines as lead sponsor.

NCT NCT01894919
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01894919 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIIb, Open Label, Multi Center Extension Study of V72_28 to Assess Antibody Persistence, and the Safety and Tolerability of a Booster Dose After the Completion of the Vaccination Course in Study V72_28
Lead sponsor
Novartis Vaccines
Phase
Phase 3
Overall status
Completed
Start date
June 30, 2013
Completion date
November 30, 2015
Enrollment
851 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

meningoccocal disease, meningococcal meningitis